iCAD (NASDAQ:ICAD) Rating Lowered to “Sell” at StockNews.com

iCAD (NASDAQ:ICAD) was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating in a report released on Wednesday.

iCAD Price Performance

ICAD opened at $3.61 on Wednesday. iCAD has a 1 year low of $1.18 and a 1 year high of $3.78. The stock’s 50 day simple moving average is $2.30 and its 200 day simple moving average is $1.86. The firm has a market cap of $95.81 million, a price-to-earnings ratio of -27.77 and a beta of 1.47.

Hedge Funds Weigh In On iCAD

Hedge funds have recently modified their holdings of the company. waypoint wealth counsel increased its holdings in iCAD by 44.0% during the 4th quarter. waypoint wealth counsel now owns 14,400 shares of the technology company’s stock valued at $26,000 after purchasing an additional 4,400 shares during the period. Thompson Davis & CO. Inc. purchased a new position in iCAD during the 4th quarter valued at $31,000. PKS Advisory Services LLC purchased a new position in iCAD during the 4th quarter valued at $53,000. Wells Fargo & Company MN lifted its position in shares of iCAD by 51.3% in the 4th quarter. Wells Fargo & Company MN now owns 39,542 shares of the technology company’s stock worth $72,000 after purchasing an additional 13,402 shares during the period. Finally, Summit Trail Advisors LLC purchased a new stake in shares of iCAD in the 4th quarter worth about $214,000. Hedge funds and other institutional investors own 24.61% of the company’s stock.

iCAD Company Profile

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.